EWTXEdgewise Therapeutics, Inc.

Nasdaq edgewisetx.com


$ 19.31 $ 0.28 (1.47 %)    

Thursday, 02-May-2024 15:59:48 EDT
QQQ $ 429.07 $ 5.38 (1.28 %)
DIA $ 382.31 $ 3.34 (0.88 %)
SPY $ 505.01 $ 4.68 (0.94 %)
TLT $ 88.87 $ 0.38 (0.43 %)
GLD $ 213.12 $ -0.66 (-0.31 %)
$ 19.29
$ 19.04
$ 0.00 x 0
$ 0.00 x 0
$ 18.70 - $ 19.48
$ 5.12 - $ 20.90
1,158,650
na
1.23B
$ 1.19
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 02-22-2024 12-31-2023 10-K
2 11-09-2023 09-30-2023 10-Q
3 08-10-2023 06-30-2023 10-Q
4 05-11-2023 03-31-2023 10-Q
5 02-23-2023 12-31-2022 10-K
6 11-03-2022 09-30-2022 10-Q
7 08-04-2022 06-30-2022 10-Q
8 05-11-2022 03-31-2022 10-Q
9 02-24-2022 12-31-2021 10-K
10 11-10-2021 09-30-2021 10-Q
11 08-09-2021 06-30-2021 10-Q
12 05-13-2021 03-31-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 rbc-capital-maintains-outperform-on-edgewise-therapeutics-raises-price-target-to-32

RBC Capital analyst Leonid Timashev maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and raises the price tar...

 truist-securities-maintains-buy-on-edgewise-therapeutics-maintains-25-price-target

Truist Securities analyst Srikripa Devarakonda maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Buy and maintains $25 pr...

 wedbush-reiterates-outperform-on-edgewise-therapeutics-maintains-26-price-target

Wedbush analyst Laura Chico reiterates Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and maintains $26 price target.

 edgewise-therapeutics-reports-two-year-topline-results-from-arch-open-label-trial-of-sevasemten-in-adults-with-becker-muscular-dystrophy-sevasemten-was-well-tolerated

"We are pleased by the promising and consistent functional results observed over two years of treatment with sevasemten, to...

 rbc-capital-reiterates-outperform-on-edgewise-therapeutics-maintains-28-price-target

RBC Capital analyst Leonid Timashev reiterates Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and maintains $28 price...

 piper-sandler-initiates-coverage-on-edgewise-therapeutics-with-overweight-rating-announces-price-target-of-48

Piper Sandler analyst Yasmeen Rahimi initiates coverage on Edgewise Therapeutics (NASDAQ:EWTX) with a Overweight rating and ...

 edgewise-therapeutics-to-present-on-edg-5506-for-the-treatment-of-becker-muscular-dystrophy-at-the-2024-mda-clinical-and-scientific-conference

– Company to host an Industry Forum to discuss its approach to protecting and preserving dystrophic muscle featuring key opinio...

 edgewise-therapeutics-q4-eps-047-misses-043-estimate

Edgewise Therapeutics (NASDAQ:EWTX) reported quarterly losses of $(0.47) per share which missed the analyst consensus estimate ...

 insiders-buying-edgewise-therapeutics-and-2-other-stocks

Although U.S. stocks closed higher on Thursday, there were a few notable insider trades.

 why-transcode-therapeutics-shares-are-trading-lower-by-over-24-here-are-other-stocks-moving-in-fridays-mid-day-session

Shares of TransCode Therapeutics, Inc. (NASDAQ: RNAZ) fell sharply during Friday’s session. TransCode Therapeutics priced a 5,...

 whats-going-on-with-edgewise-therapeutics-stock

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) shares are trading higher Friday after the company announced the pricing of its $240 ...

 world-acceptance-posts-upbeat-earnings-joins-kaman-spirit-airlines-and-other-big-stocks-moving-higher-on-friday

U.S. stocks traded higher, with the Dow Jones index gaining around 50 points on Friday. Shares of World Acceptance Corporatio...

 edgewise-therapeutics-highlights-2023-accomplishments-and-anticipated-milestones-for-2024-at-the-42nd-annual-jp-morgan-healthcare-conference

Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company, will present today at the 42nd ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION